Filter Publications By:

01/06/2015

Clin. Exp. Allergy, 2010; 40(7):1025-35.

Allergen-specific T cell responses to immunotherapy monitored by CD154 and intracellular cytokine expression.

Campbell JD, Buchmann P, Kesting S, Cunningham CR, Coffman RL, Hessel EM.

01/06/2015

Thorax, 2014, Jan 24. doi: 10.1136/thoraxjnl-2013-204605

A limited CpG-containing oligodeoxynucleotide therapy regimen induces sustained suppression of allergic airway inflammation in mice.

Campbell JD, Kell SA, Kozy HM, Lum JA, Sweetwood R, Chu M, Cunningham CR, Salamon H, Lloyd CM, Coffman RL, Hessel EM.

01/06/2015

Nat. Immunol., 2006; 7(6):539-41.

Origins of the Th1-Th2 model: a personal perspective.

Robert L. Coffman.

01/06/2015

Nature Medicine, 2007; 13(5):552-559.

Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists.

Holger Kanzler, Franck J Barrat, Edith M Hessel & Robert L Coffman.

01/06/2015

The Expert Review of Vaccines, 2007; 6(5):747-759.

Immunostimulatory DNA as a Vaccine Adjuvant.

Debbie Higgins, Jason D Marshal, Paula Traquina, Gary Van Nest and Brian Livingston.

01/06/2015

Immunological Reviews, 2008; 223:271-283.

Development of TLR inhibitors for the treatment of autoimmune diseases.

Frank J. Barrat and Robert L. Coffman.

01/06/2015

Immunity, 2010; 33(4):492-503.

Vaccine adjuvants: putting innate immunity to work.

Coffman, RL, Sher A, Seder RA.

01/06/2015

Sci. Transl. Med., 2011; 3(93):93rv2.

Assessing the safety of adjuvanted vaccines.

Ahmed SS, Plotkin SA, Black S, Coffman RL.

01/05/2015

Vaccine. 2013 Nov 4;31(46):5306-13.

Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease.

Janssen RS, Mangoo-Karim R, Pergola PE, Girndt M, Namini H, Rahman S, Bennett SR, Heyward WL, Martin JT.

01/05/2015

Vaccine. 2013 Nov 4;31(46):5300-5.

Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40–70 years of age.

Heyward WL, Kyle M, Blumenau J, Davis M, Reisinger K, Kabongo ML, Bennett S, Janssen RS, Namini H, Martin JT.